Coronavirus Notebook: EMA Hones In On COVID-19 Activities, Russia’s Sputnik V Launches In India
Executive Summary
A new study shows that the immune response to Pfizer/BioNTech’s Comirnaty in elderly people is 3.5-fold greater when the second dose is given after 12 weeks rather than three. The WHO has OKd the emergency use of a Chinese vaccine.
You may also be interested in...
Coronavirus Notebook: COVAX Exceeds Vaccine Funding Target, Canada OKs Mix-And-Match Dosing
In a sign of growing support for more equitable vaccine distribution, many donors have pledged either money or doses to lower-income economies. The World Health Organization has granted emergency use listing to another Chinese vaccine, and Russia’s Sputnik V is to be produced in Bahrain for the MENA region.
Medicines Patent Pool Prepared To Step In On Vaccines
The Medicines Patent Pool says it is ready to step in to assist with voluntary licensing and technology transfer around COVID-19 vaccines, following US support for an IP waiver.
Speed Bumps Ahead For IP Waiver, But Will It Nudge Voluntary Licensing?
IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.